Modulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100

British Journal of Cancer

Volumn 98, Issue 10, 2008, Pages 1630-1632

  Smith, N F ^a   Baker, S D ^b,d   Gonzalez, F J ^a   Harris, J W ^c   Figg, W D ^a   Sparreboom, A ^a,d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c Bioavailability Systems LLC   (United States)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

CYP3A4 transgenic; Grapefruit; Metabolism; OSI 420; OSI 774; Tarceva

Indexed keywords

ANTINEOPLASTIC AGENT; BAS 100; CYTOCHROME P450 3A4; ENZYME INHIBITOR; ERLOTINIB; OSI 420; TEMAZEPAM;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ISOLATION; DRUG METABOLISM; DRUG POTENCY; FEMALE; GRAPEFRUIT JUICE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; WILD TYPE;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; BEVERAGES; BIOLOGICAL AVAILABILITY; CITRUS PARADISI; CYTOCHROME P-450 CYP3A; ENZYME INHIBITORS; ESTERS; FEMALE; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RANDOM ALLOCATION; SPIRO COMPOUNDS;

EID: 43649104767     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604353     Document Type: Article

References (18)

1. Bailer AJ (1988) Testing for the equality of area under the curves when using destructive measurement techniques. J Pharmacokinet Biopharm 16: 303-309
2. Bailey DG, Malcolm J, Arnold O, Spence JD (2004) Grapefruit juice-drug interactions. 1998. Br J Clin Pharmacol 58: S831-S840; discussion S841-S843
3. Bailey DG, Spence JD, Munoz C, Arnold JM (1991) Interaction of citrus juices with felodipine and nifedipine. Lancet 337: 268-269
4. Frohna P, Lu J, Eppler S, Hamilton M, Wolf J, Rakhit A, Ling J, Kenkare-Mitra SR, Lum BL (2006) Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects. J Clin Pharmacol 46: 282-290
5. Granvil CP, Yu AM, Elizondo G, Akiyama TE, Cheung C, Feigenbaum L, Krausz KW, Gonzalez FJ (2003) Expression of the human CYP3A4 gene in the small intestine of transgenic mice: in vitro metabolism and pharmacokinetics of midazolam. Drug Metab Dispos 31: 548-558
6. Hellriegel ET, Bjornsson TD, Hauck WW (1996) Interpatient variability in bioavailability is related to the extent of absorption: implications for bioavailability and bioequivalence studies. Clin Pharmacol Ther 60: 601-607
7. Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C, Eckhardt SG, Tolcher A, Britten CD, Denis L, Ferrante K, von Hoff DD, Silberman S, Rowinsky EK (2001) Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19: 3267-3279
8. Li F, Desai PB, Harris JW (2006a) Modulation of hepatic and intestinal CYP3A4 and P-gp expression and activity by BAS 100, a naturally occurring bioavailability-boosting agent from grapefruit juice. Drug Metab Rev 38(Suppl 2): 116
9. Li F, Kulkarni A, Pauletti G, Desai P (2007a) Influence of BAS 100, a spiro-ortho -ester, isolated from grapefruit juice on the activity and expression of drug metabolizing enzymes and transporters. AAPS J 9(Suppl 2): Abstract T3402
10. Li J, Karlsson MO, Brahmer J, Spitz A, Zhao M, Hidalgo M, Baker SD (2006b) CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. J Natl Cancer Inst 98: 1714-1723
11. Li J, Zhao M, He P, Hidalgo M, Baker SD (2007b) Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res 13: 3731-3737
12. Ling J, Johnson KA, Miao Z, Rakhit A, Pantze MP, Hamilton M, Lum BL, Prakash C (2006) Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers. Drug Metab Dispos 34: 420-426
13. Lu JF, Eppler SM, Wolf J, Hamilton M, Rakhit A, Bruno R, Lum BL (2006) Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. Clin Pharmacol Ther 80: 136-145
14. Strother RM, Jones DR, Skaar T, Huh WS, Porter J, Foster A, Sweeney C (2006) Erlotinib-associated rash correlates with plasma levels at steady state. J Clin Oncol ASCO Annual Meeting Proceedings Part I. 24(18S): 13008
15. Tan AR, Yang X, Hewitt SM, Berman A, Lepper ER, Sparreboom A, Parr AL, Figg WD, Chow C, Steinberg SM, Bacharach SL, Whatley M, Carrasquillo JA, Brahim JS, Ettenberg SA, Lipkowitz S, Swain SM (2004) Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J Clin Oncol 22: 3080-3090
16. Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, Cagnoni PJ (2007) Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 13: 3913-3921
17. Yuan J (1993) Estimation of variance for AUC in animal studies. J Pharm Sci 82: 761-763
18. Zhao M, He P, Rudek MA, Hidalgo M, Baker SD (2003) Specific method for determination of OSI-774 and its metabolite OSI-420 in human plasma by using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 793: 413-420